These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18559291)

  • 1. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.
    Davidson JR; Wittchen HU; Llorca PM; Erickson J; Detke M; Ball SG; Russell JM
    Eur Neuropsychopharmacol; 2008 Sep; 18(9):673-81. PubMed ID: 18559291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
    Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.
    Allgulander C; Hartford J; Russell J; Ball S; Erickson J; Raskin J; Rynn M
    Curr Med Res Opin; 2007 Jun; 23(6):1245-52. PubMed ID: 17559726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trials.
    Beesdo K; Hartford J; Russell J; Spann M; Ball S; Wittchen HU
    J Anxiety Disord; 2009 Dec; 23(8):1064-71. PubMed ID: 19643572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.
    Nicolini H; Bakish D; Duenas H; Spann M; Erickson J; Hallberg C; Ball S; Sagman D; Russell JM
    Psychol Med; 2009 Feb; 39(2):267-76. PubMed ID: 18485261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.
    Russell JM; Weisberg R; Fava M; Hartford JT; Erickson JS; D'Souza DN
    Depress Anxiety; 2008; 25(7):E1-11. PubMed ID: 17587217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A continuous responder analysis from a long-term trial of duloxetine treatment for generalized anxiety disorder: implications for the randomized withdrawal relapse prevention study design.
    Llorca PM; Bodkin JA; Spann M; Ball SG; Russell JM; Ball SG
    J Clin Psychopharmacol; 2009 Feb; 29(1):96-7. PubMed ID: 19142122
    [No Abstract]   [Full Text] [Related]  

  • 9. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment.
    Pollack MH; Endicott J; Liebowitz M; Russell J; Detke M; Spann M; Ball S; Swindle R
    J Psychiatr Res; 2008 Oct; 42(12):1042-9. PubMed ID: 18221755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China.
    Wu WY; Wang G; Ball SG; Desaiah D; Ang QQ
    Chin Med J (Engl); 2011 Oct; 124(20):3260-8. PubMed ID: 22088518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder.
    Fava M; Wiltse C; Walker D; Brecht S; Chen A; Perahia D
    J Affect Disord; 2009 Mar; 113(3):263-71. PubMed ID: 18625521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
    Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
    Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder.
    Bodkin JA; Allgulander C; Llorca PM; Spann ME; Walker DJ; Russell JM; Ball SG
    Hum Psychopharmacol; 2011 Apr; 26(3):258-66. PubMed ID: 21678494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
    Brannan SK; Mallinckrodt CH; Detke MJ; Watkin JG; Tollefson GD
    J Psychiatr Res; 2005 Mar; 39(2):161-72. PubMed ID: 15589564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial.
    Ball S; Marangell LB; Lipsius S; Russell JM
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():217-21. PubMed ID: 23313564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial.
    Amsterdam JD; Brunswick DJ; Gibertini M
    J Psychiatr Res; 2004; 38(3):259-65. PubMed ID: 15003431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
    Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
    J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of depression relapse: re-initiation of duloxetine treatment or dose increase.
    Fava M; Detke MJ; Balestrieri M; Wang F; Raskin J; Perahia D
    J Psychiatr Res; 2006 Jun; 40(4):328-36. PubMed ID: 16678205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.